EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors

Sam Schulman, Vinai Bhagirath, Noel Chan, Federico Germini, Rick Ikesaka, Alfonso Iorio, Siraj Mithoowani, Jeff I Weitz, Peter L Gross

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.07.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Sam Schulman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada; Department of Obstetric…. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Blood Coagulation Factors, Rivaroxaban, Pyridones. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Octapharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: It is uncertain whether prothrombin complex concentrate (PCC) improves hemostasis in patients on treatment with oral factor Xa-inhibitors (XaI) who require emergency surgery. OBJECTIVES: To evaluate whether, in patients with therapeutic levels of oral XaI, preoperative PCC prevents excessive bleeding during and after emergency surgery and is not associated with thrombotic complications. METHODS: We conducted a prospective cohort study wherein a fixed 2000 IU dose of 4-factor PCC was given to patients taking oral XaI with plasma XaI levels of at least 75 ng/mL before the emergency surgery with an expected blood loss of at least 50 mL. Patients were followed for 30 days. The primary efficacy outcome was the incidence of normal or mildly abnormal surgical hemostasis, as assessed by the surgeon; primary safety outcome was the incidence of thromboembolic events within 7 days. RESULTS: We included 20 patients, of which 50% were female, on apixaban (75%) or rivaroxaban (25%) with median XaI level of 128 ng/mL (range, 77-497 ng/mL). The median duration of surgery was 2 hours 42 minutes (range, 15 minutes to 8 hours 17 minutes). Normal or mildly abnormal hemostasis was observed in 16 patients (80%); 2 patients had moderately abnormal and 2 had severely abnormal hemostasis, 1 each of those was considered due to local or technical factors. There were 4 deaths (20%) secondary to underlying disease and 1 incidental pulmonary embolism in a patient with cancer. CONCLUSION: A fixed dose of PCC appears to control hemostasis in patients with therapeutic plasma levels of apixaban or rivaroxaban requiring emergency surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor Xa InhibitorsBlood Coagulation FactorsRivaroxabanPyridonesPyrazolesHumansFemaleMaleProspective StudiesAgedMiddle AgedAdministration, OralTreatment OutcomeBlood Loss, SurgicalEmergenciesAged, 80 and overThromboembolismTime FactorsPostoperative HemorrhageHemostasisSurgical Procedures, OperativeHemostasis, Surgical

Stichwörter der Autor:innen

apixabanhemostasis surgicalprospective studiesprothrombin complex concentratesrivaroxaban

Substanzen

Factor Xa Inhibitorsprothrombin complex concentratesBlood Coagulation FactorsRivaroxabanPyridonesapixabanPyrazoles

Autor:innen und Institutionen

  • Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada; Department of Obstetrics and Gynecology and Perinatal Medicine, The First I.M. Sechenov Mosco…
  • Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Hamilton, Ontario, Canada.
  • Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada; Clinical Epidemiology and Research Center, Istituto di Ricovero e Cura a Carattere Scientific…
  • Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada.
  • Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, O…

Förderung

  • Octapharma AG

Zitieren

APA

Schulman, S., Bhagirath, V., Chan, N., Germini, F., Ikesaka, R., Iorio, A., Mithoowani, S., Weitz, J. I., & Gross, P. L. (2024). Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.07.002

Vancouver

Schulman S, Bhagirath V, Chan N, Germini F, Ikesaka R, Iorio A, et al. Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.07.002

BibTeX
@article{Schulman2024,
  author = {Schulman, Sam and Bhagirath, Vinai and Chan, Noel and Germini, Federico and Ikesaka, Rick and Iorio, Alfonso and Mithoowani, Siraj and Weitz, Jeff I and Gross, Peter L},
  title = {Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.07.002}
}
Kostenlos starten →